Jennifer Yoest, MD
- Director, Somatic Molecular Testing, UH Cleveland Medical Center
- Assistant Professor, CWRU School of Medicine
- Specialty: Pathology-Clinical
Location:UH Cleveland Medical Center
11100 Euclid Ave
Cleveland, OH 44106
- Call: 216-286-4283
Biography: Jennifer Yoest, MD
Certifications & Memberships
- Molecular Genetic Pathology - American Board of Pathology
- Anatomic and Clinical Pathology - American Board of Pathology
Fellowship | Molecular Genetic Pathology
Molecular Genetic Pathology - Washington University School Of Medicine In St Louis (2018 - 2019)
Residency | Anatomic and Clinical Pathology
Anatomic and Clinical Pathology - University Of Pittsburgh Medical Center UPMC (2014 - 2018)
University Of Pittsburgh School Of Medicine (2009 - 2014)
University Of Kansas (2009)
Jennifer Yoest, MD is a board-certified clinical pathologist at University Hospitals Cleveland Medical Center. Her clinical and research interests include molecular test development, immune-related adverse events in immune checkpoint inhibitor therapy, and molecular measurable residual disease in acute myeloid leukemia.
After earning her Bachelor of Science in biology with an emphasis on genetics from the University of Kansas in 2009, Dr. Yoest went on to earn her medical doctorate at the University of Pittsburgh School of Medicine in 2014, where she also completed a post-sophomore fellowship in pathology.
Dr. Yoest completed her residency training in anatomic and clinical pathology at University of Pittsburgh Medical Center in 2018 followed by a fellowship in molecular genetic pathology at Washington University St. Louis School of Medicine in 2019. She joined University Hospitals in 2019 as faculty in the Division of Genomic and Molecular Pathology.
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Lauren Kerr did not disclose any Outside Relationships with Industry.